Linked Life Data

10216808

Source:http://linkedlifedata.com/resource/pubmed/id/10216808

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1999-6-22
pubmed:abstractText
A double-blind comparator study was performed in 528 hypertensive patients [baseline sitting diastolic blood pressure (SitDBP) 95-114 mmHg]. The primary objective was to compare the incidence of drug-related cough in patients treated with enalapril and eprosartan. The secondary objective was to compare antihypertensive efficacy between treatments. This paper reports the results of a prespecified subgroup analysis performed in the 40 black patients recruited into the study. Eprosartan was titrated from 200 mg b.i.d. to 300 mg b.i.d. and enalapril from 5 mg o.d. to 20 mg o.d. over 12 weeks. Hydrochlorothiazide (HCTZ) 12.5-25 mg o.d. could be added where required to the treatment for the final six weeks of the titration phase if SitDBP > or = 90 mmHg. Patients received the maximum titrated dosage during the maintenance phase. In the study overall, the incidence of cough at monotherapy endpoint was significantly higher in the enalapril-treated group than in the eprosartan-treated group (p = 0.018). This trend was reflected in the black subgroup but the numbers were too small to confirm significance. At study endpoint the mean change in SitDBP was -10.5 +/- 1.9 mmHg and -9.6 +/- 2.4 mmHg for eprosartan-treated and enalapril-treated patients, respectively. The mean change in SitSBP for eprosartan-treated black patients was -18.8 +/- 3.5 mmHg and for enalapril-treated patients was -10.5 +/- 3.7 mmHg. The black subpopulation mirrored the response of the study as a whole. Both treatments lowered BP with a further reduction evident following the addition of HCTZ at week 18. In conclusion, eprosartan is effective and appears to be safe in black hypertensive patients. The combination of eprosartan and HCTZ was also well tolerated and provided additional efficacy in those patients not responding to eprosartan alone. The incidence of treatment-associated cough in the black subgroup was low, but there were no apparent differences between treatment groups.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-7995
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
25-32
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10216808-Acrylates, pubmed-meshheading:10216808-Adult, pubmed-meshheading:10216808-African Continental Ancestry Group, pubmed-meshheading:10216808-Aged, pubmed-meshheading:10216808-Angiotensin II, pubmed-meshheading:10216808-Angiotensin-Converting Enzyme Inhibitors, pubmed-meshheading:10216808-Antihypertensive Agents, pubmed-meshheading:10216808-Blood Pressure, pubmed-meshheading:10216808-Consumer Product Safety, pubmed-meshheading:10216808-Cough, pubmed-meshheading:10216808-Double-Blind Method, pubmed-meshheading:10216808-Enalapril, pubmed-meshheading:10216808-Female, pubmed-meshheading:10216808-Humans, pubmed-meshheading:10216808-Hypertension, pubmed-meshheading:10216808-Imidazoles, pubmed-meshheading:10216808-Male, pubmed-meshheading:10216808-Middle Aged, pubmed-meshheading:10216808-Thiophenes
pubmed:year
1999
pubmed:articleTitle
Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
pubmed:affiliation
VA Medical Center, West Los Angeles, CA 90073, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study